At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 11, 2026 at 16:05 ET
Longeveron (LGVN) closed the first tranche of a $30 million private placement, raising $15 million upfront through a mix of common and convertible preferred stock issued at $0.52 per share. Proceeds extend the company's cash runway into Q4 2026, covering the pivotal Phase 2b ELPIS II trial readout for HLHS in Q3 2026. An additional $15 million is contingent on clinical milestones and share price performance.
- Raised $15 million in initial tranche of private placement, with up to $15 million more contingent on milestones.
- Issued 6,013,384 Class A common shares and Series A Preferred Shares convertible into 22,832,770 common shares, all priced at $0.52 per share.
- Cash runway extended into Q4 2026, past the ELPIS II trial topline data readout in Q3 2026.
- Investors include Coastlands Capital, Janus Henderson Investors, Logos Capital, and Kalehua Capital.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access